[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

20181,116 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 19, Issue 6, pp. 825-833

Field-Weighted Citation Impact: 105.24